48 results
8-K
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
the Placement Agent for certain of its Offering-related expenses, including reimbursement for non-accountable expenses, legal fees and other out
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
raised in this offering. We have also agreed to reimburse the placement agent for certain of its offering related expenses, including reimbursement for non … reimbursement for non-accountable expenses, legal fees and other out-of-pocket expenses in the amount of up to $112,500, and for its clearing expenses
8-K
EX-3.1
6nmwu5r2aaaybl83
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
8-K
EX-10.1
lx4j6c
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
u23za6q
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
lbzpaqe
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
8mihh3cx
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
424B3
t9rro1q0dnj53e
12 Apr 21
Prospectus supplement
1:44pm
S-3
ccw00 h92
2 Apr 21
Shelf registration
12:00am
8-K
EX-10.1
q892z0
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
n5qbkts4w8a
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm